World's First Experience of the Low-dose radionuclide inhalation therapy in the treatment of COVID-19-associated viral pneumonia: phase 1/2 clinical trial.

Inhaled low-dose radionuclide therapy of 99mTc aerosol affects the major prognostic indicators of COVID-19-related pneumonia restraining inflammatory response. Overall, we identified no evidence of major adverse events in the group receiving radionuclide.